Association of the Sirtuin and Mitochondrial Uncoupling Protein Genes with Carotid Plaque

Chuanhui Dong1*, David Della-Morte1,4,9, Liyong Wang2, Digna Cabral1, Ashley Beecham2, Mark S. McClendon1, Corneliu C. Luca1, Susan H. Blanton2, Ralph L. Sacco1,2,3, Tatjana Rundek1,3

1 Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 2 John T. McDonald Department of Human Genetics, John P. Hussman Institute for Human Genomics Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 3 Department of Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 4 Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy

Abstract

Objective: Sirtuins (SIRTs) and mitochondrial uncoupling proteins (UCPs) have been implicated in cardiovascular diseases through the control of reactive oxygen species production. This study sought to investigate the association between genetic variants in the SIRT and UCP genes and carotid plaque.

Methods: In a group of 1018 stroke-free subjects from the Northern Manhattan Study with high-definition carotid ultrasonography and genotyping, we investigated the associations of 85 single nucleotide polymorphisms (SNPs) in the 11 SIRT and UCP genes with the presence and number of carotid plaques, and evaluated interactions of SNPs with sex, smoking, diabetes and hypertension as well as interactions between SNPs significantly associated with carotid plaque.

Results: Overall, 60% of subjects had carotid plaques. After adjustment for demographic and vascular risk factors, T-carriers of the SIRT6 SNP rs107251 had an increased risk for carotid plaque (odds ratio, OR = 1.71, 95% CI = 1.23–2.37, Bonferroni-corrected p = 0.03) and for a number of plaques (rate ratio, RR = 1.31, 1.18–1.45, Bonferroni-corrected p = 1.4 × 10⁻⁴), whereas T-carriers of the UCP5 SNP rs5977238 had an increased risk for carotid plaque (OR = 0.49, 95% CI = 0.32–0.74, Bonferroni-corrected p = 0.02) and plaque number (RR = 0.64, 95% CI = 0.52–0.78, Bonferroni-corrected p = 4.9 × 10⁻⁴). Some interactions with a nominal p ≤ 0.01 were found between sex and SNPs in the UCP1 and UCP3 gene; between smoking, diabetes, hypertension and SNPs in UCP5 and SIRT5; and between SNPs in the UCP5 gene and the UCP1, SIRT1, SIRT3, SIRT5, and SIRT6 genes in association with plaque phenotypes.

Conclusion: We observed significant associations between genetic variants in the SIRT6 and UCP5 genes and atherosclerotic plaque. We also found potential effect modifications by sex, smoking and vascular risk factors of the SIRT/UCP genes in the associations with atherosclerotic plaque. Further studies are needed to validate our observations.

Introduction

Atherosclerosis is a complex disorder and underlying cause of ischemic strokes and cardiovascular diseases (CVD) [1]. Presence of carotid plaque has been widely used to assess the risk of future clinical atherosclerotic disease. Atherosclerotic plaque reflects biologically distinct atherosclerotic phenotype [1]. The heritability of carotid plaque is 23–50%, indicating an important role of genetic contribution to atherosclerosis [2,3]. Genes controlling the oxidative stress, balance between production and removal of reactive oxygen species (ROS), are strongly implicated in mechanisms of atherosclerosis, stroke and cardiovascular disease (CVD) [4]. Oxidative stress plays a major role in age-dependent atherosclerosis by the enhancement of endothelial dysfunction and reduction of nitric oxide (NO) bioactivity, determining vascular aging independently of other traditional vascular risk factors [5].

Sirtuins (SIRTs) are a family of nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylases involved in chromatin remodeling, cellular metabolism and lifespan regulation. [6] Mitochondrial Uncoupling Proteins (UCPs) are a family of inner mitochondrial membrane proteins capable of driving the ATP synthase pathway via regulation of the proton electrochemical gradient [7]. SIRTs and UCPs may modify the oxidative stress and therefore affect the risk of atherosclerosis [6,8,9]. Moreover, the up or down regulation and the enzymatic activity of SIRT/UCP proteins have been related to the degree of tolerance to brain ischemia [10].
Associations of SIRTs and UCPs with the traditional vascular risk factors (RF) have been previously reported. Variants of the SIRT1, SIRT2, SIRT6, UCP1, UCP2, and UCP3 genes have been related to diabetes [11], obesity [12,13], serum high-density lipoprotein cholesterol (HDL) [14], and inflammation [15]. However, few studies have examined the direct association between these genes and carotid atherosclerotic plaque, a subclinical marker of vascular disease [16].

We sought to examine the associations between variance of the 6 SIRT and 5 UCP genes and the presence and number of carotid plaque in a stroke-free population from a population-based cohort. Based on our previous observation that SIRT1/UCP2 pathways protect against cerebral ischemia with a synergistic effects in maintaining oxidative balance and ATP production, resulting in an increase in cellular survival and modification in response to different stimuli, such as oxidative stress [10], we hypothesized that variants in sirtuin and UCP genes may have functional significance in the pathophysiology of subclinical vascular disease.

Materials and Methods

Subjects

This study consisted of a sample of 1018 stroke-free participants from the Northern Manhattan Study (NOMAS) who had carotid ultrasound performed and a genome-wide association (GWAS) data available. We have reported the detailed ascertainment scheme of the NOMAS previously [17]. Briefly, NOMAS participants were eligible if they had never been diagnosed with a stroke, were at least 40 years of age, and resided for at least 3 months in a household with a telephone in northern Manhattan. At enrollment, demographic characteristics and RF were collected through standardized questionnaires and laboratory tests. Hypertension was defined as a systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg, or a history of hypertension and anti-hypertension treatment; diabetes mellitus was defined as fasting blood glucose ≥126 mg/dl, or use of insulin or hypoglycemic medications; hypercholesterolemia was defined as total cholesterol ≥240 mg/dl or a history of taking lipid lowering medications. Smoking was dichotomized as ever or never smoking, physical activity as any leisure-time activity or none, and alcohol drinking as light to moderate (≥1 drink/month but <2 drinks/day), none or other [18]. Body mass index (BMI, kg/m²) and waist-to-hip ratio (WHR) were calculated based on the measured weight, height, waist circumference and hip circumference.

All subjects provided informed consent to participate, and the study was approved by the Institutional Review Boards of Columbia University in New York and the University of Miami.

Carotid Plaque Ultrasound Imaging

High-definition carotid ultrasoundography was performed according to a standard scanning and reading protocol by a sonologist trained and certified in performing ultrasound research studies. Detailed descriptions of the methods and reliability studies have been published previously [16]. In brief, carotid ultrasound imaging was performed on a GE Logiq 700 system with a multifrequency 9/13-MHz linear-array transducer. Both internal and common carotid arteries and the bifurcations were examined for the presence of atherosclerotic plaque, defined as an area of focal wall thickening more than 50% greater than surrounding wall thickness. The sum of plaques insonated in all carotid artery segments was also analyzed.

Genotyping

We analyzed variants of the SIRT and UCP genes available from a genome-wide association study performed on the Genome-Wide Human SNP Array 6.0 chip (AffyMetrix). DNA samples were processed according to Affymetrix procedures. The arrays were scanned on the GeneChip Scanner 3000 7G. Image data were analyzed using the Genotyping Console™. Vigorous quality control was applied to the samples and SNPs. Samples were removed from further analysis if they had call rates below 95%, relatedness, sex discrepancies, or were outliers beyond 6 SD from the mean using EIGENSTRAT [19]. SNPs with severe deviation from Hardy-Weinberg equilibrium (p<1E-06) or a genotyping call rate less than 95% were also removed using PLINK 1.05 [20]. After quality control, a total of 85 UCP/SIRT SNPs in the 11 UCP and SIRT genes were included in the final analysis of this study (table S1).

Statistical Analyses

To reduce potential bias due to population stratification, we first performed principal component analysis to examine population substructure using EIGENSTRAT and selected the plaque associated principle components (PCAs) as genomic control variables. Univariate analysis was performed to identify demographic characteristics and RF associated with presence of carotid plaque (p<0.05) in order to include significant factors as covariates in the final genetic association analysis of the UCP and SIRT variants.

For single SNP-based association analyses, we examined the additive genetic effects of the UCP and SIRT variants on the presence of carotid plaque using logistic regression models and on the number of carotid plaques using Poisson regression models. These models were adjusted for age, sex, smoking, hypertension, diabetes and WHR, as well as for genomic control variable PCA2 and PCA4. PCAs associated with carotid plaque among the top 5 PCAs (p<0.05 for PCA2 and PCA4, and p>0.05 for PCA1, PCA3, PCA5). Zero-inflation modelling did not detect an excess of zeros in the distribution of plaque numbers in Poisson regression analysis.

For haplotype-based analysis, linkage disequilibrium (LD) blocks were first identified for each gene using Haploview [21]. Haplotypes for the SNPs in the LD block were then estimated for each subject using the E-M algorithm in PLINK. Similar to SNP-based analysis, an additive effect of a haplotype was examined using generalized linear regression models via SAS GENMOD procedure by coding 0, 1 and 2 based on the copy number of the haplotype. We limited haplotype analysis to the genes with a SNP showing an association after correction for multiple testing and to haplotypes with a frequency of at least 5%. All the analyses were performed using the generalized linear regression analysis procedure GENMOD in SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Bonferroni correction was employed to control for multiple testing based on the effective number of tests. For SNP-based analysis, the effective number of tests was defined as the sum of the LD blocks and singleton SNPs [22]. A total of 16 LD blocks were identified and 14 SNPs were not located in any LD block (Figure S1), leading to an effective test number of 30. For haplotype-based analysis, the analysis was limited to the genes with a SNP showing an association after correction for multiple testing to the haplotypes with a frequency of at least 5%. Therefore, a total of 23 haplotypes were investigated.

To explore sex and RF effect modification on the associations between gene variants and plaque, we examined SNP-by-sex and SNP-by-RF interactions and performed stratified analyses if the interaction terms in the models had p≤0.01. We also explored SNP-by-SNP interactions between the SNPs significantly associ-
ated with plaque and the SNPs in other genes and then conducted stratified analysis if the p value for interaction term was \( \leq 0.01 \).

**Results**

Subject Characteristics, Vascular Risk Factors and Carotid Plaque Presence

Among 1018 subjects (mean age: 70 ± 9), 61% were women, 67% Caribbean Hispanic, 17% Black, and 15% White. Overall, 60% of subjects had carotid plaques, 25% had three or more plaques (Figure 1), 62% had hypertension, 18% had diabetes, and 52% were smokers. Univariate analysis showed that age, sex, race/ethnicity, smoking, hypertension, diabetes, and waist-to-hip ratio were associated with the presence of carotid plaque (Table 1).

Associations of SNPs with Presence of Carotid Plaque and with a Number of Carotid Plaque

The SNPs significantly associated with the presence and number of carotid plaques (\( p \leq 0.05 \) adjusted for multiple testing) are reported in Table 2. Two SNPs, rs107251 in SIRT6 and rs5977238 in UCP5, were associated with both presence and number of carotid plaque after correction for multiple testing. T-carriers of SIRT6 SNP rs107251 had an increased risk (OR 1.71, 95% CI = 1.23–2.37, \( p = 0.03 \)) for carotid plaque presence and for a number of carotid plaques (RR 1.31, 95% CI = 1.18–1.45, \( p = 1.4 \times 10^{-5} \)), whereas T-carriers of UCP5 SNP rs5977238 had a decreased risk (OR 0.49, 95% CI = 0.32–0.74, \( p = 0.02 \)) for carotid plaque presence and for a number of plaques (RR 0.64, 95% CI = 0.52–0.78, \( p = 4.9 \times 10^{-5} \)). Two additional SNPs (rs4712032 and rs12216101) in the SIRT3 gene were associated with a greater number of carotid plaques after correction for multiple testing.

Haplotypes Associated with the Presence or Number of Carotid Plaque

The results of the haplotypes analyses are presented in Table 3. Two haplotypes, TT at rs107251 and rs3760905 in the SIRT6 gene and TTTCACATT at 9 SNPs in the UCP5 gene (Figure S1), were associated with both carotid plaque phenotypes. Haplotypes within the SIRT6 gene were associated with increased risk of carotid phenotypes while within the UCP5 gene were protective.

Also, a 4-SNP haplotype GCGG of the SIRT5 gene was associated with a greater number of carotid plaques (RR 1.16, 95% CI = 1.07–1.26, adjusted \( p = 0.009 \)).

Interactions between the SIRT/UCP gene Variants and Vascular Risk Factors

Table 4 shows the interactions between SNPs and vascular risk factors with a nominal \( p \leq 0.01 \) and the genetic effects stratified by the status of the specific vascular risk factor.

For plaque presence, SNP-by-sex interaction was found for 2 potential regulatory UCP3 SNPs (rs1683356 and rs1726745; \( p = 0.01 \)). Specifically, increased risk was found for A-carrier women at UCP3 SNP rs1683356 (OR 1.42, 95% CI 1.08–1.87) but not for A-carrier men (OR 0.76, 95% CI 0.54–1.08), and decreased risk was found for G-carrier men at UCP1 SNP rs1430579 (OR 0.80, 95% CI 0.72–0.90) but not for women (RR 1.06, 95% CI 0.97–1.16). No interaction with RF was found with a nominal \( p \leq 0.01 \).

For plaque number, a SNP-by-sex interaction was found for 4 UCP1 SNPs (rs1430579, rs1472268, rs1472269, and rs629571; \( p = 0.0006 \)) at transcription factor binding sites (TFBS) (http://snpinfo.niehs.nih.gov/snpfunc.htm). The associations of several SNPs in UCP4, 5, and SIRT3, 5 with plaque number varied by smoking status, diabetes and hypertension. For example, minor allele carriers at SIRT5 SNP rs2841503 had an increased risk for great number of plaques among non-smokers (RR 1.47, 95% CI 1.20–1.82). Likewise, minor allele carriers at several UCP5 SNPs had a decreased risk of plaque number in those with diabetes but increased risk in individuals without diabetes.

Interactions between Genetic Variants

Table 5 shows the interactions with a nominal \( p \leq 0.01 \) of the two most significant SNPs (rs107251 in SIRT6 and rs5977238 in UCP5) with the SNPs in the other UCP and SIRT genes. Among T-carriers of UCP5 rs5977238, individuals with the minor allele at three UCP1, 2 SIRT3 and 1 SIRT5 SNPs had an increased risk of having plaque. Among T-carriers at SIRT6 rs107251, individuals with minor allele at two UCP5 SNPs had a lower risk of having plaque.

Discussion

In this study we report on the association of the UCP5, SIRT6 and SIRT5 gene variants with carotid plaque, a surrogate marker of atherosclerosis. Haplotype analyses confirmed and straightened these observations. Several important effect modifications of these relationships were found by sex (for the associations with UCP and UCP3) and RF including smoking (for the associations with SIRT5 and UCP4), hypertension (for the associations with SIRT3, SIRT5, and UCP5), and diabetes (for the associations with SIRT5 and UCP5). Some gene-gene interactions have also shown among UCP5 and genetic variants in UCP1, SIRT1, SIRT3, and SIRT5 resulting in an increased risk of having plaque; and among SIRT6 and genetic variants in UCP5 leading to a decreased risk of having plaque. These results suggest that genetic variants in sirtuins and UCP genes may have an influence on the development of vascular aging phenotypes, independent of common RF.

The proteins expressed by the SIRT and UCP genes have been involved in the mechanisms leading to aging and age-dependent atherosclerosis [6,23]. Age-dependent arterial wall phenotypic changes make cardiovascular system more susceptible to oxidative damage and an increased risk of CVD even in the absence of traditional RF. Several mechanisms underlay vascular aging [3]. Oxidative stress is one of the main mechanisms leading to overt...
atherosclerosis in elderly [24]. Age-dependent mitochondrial impairment, especially in the function of proteins that regulates the mitochondrial physiology, such as UCPs, is fundamental for ROS mediated cell damage [25]. Sirtuins are histone deacetylases that are implicated in many cellular processes including cell cycle regulation, fatty acid metabolism, lifespan regulation and apoptosis [6]. There is growing evidence that UCPs and SIRTs may be involved in the mechanisms leading to atherosclerosis by ROS production with aging [6,23,26].

One of our main findings is that the variants in SIRT5 and SIRT6 genes were significantly associated with the risk of carotid plaque. SIRT5 is a mitochondrial sirtuin that is upregulated by caloric restriction and is involved in mitochondrial ROS production regulation [27]. The main substrates of SIRT5, cytochrome c and carbamoyl phosphate synthase suggest that SIRT5 may have role in controlling the atherosclerotic process [28,29]. SIRT6 is predominantly localized in the cellular nucleus and it is highly expressed in heart and brain [30]. Similar to SIRT3, SIRT6 is involved in DNA repair and lifespan extension although the exact mechanism is not fully elucidated [31]. The emerging role of SIRT6 in promoting proper chromatin function in several physiologic contexts, including telomere and genome stabilization, is DNA repair pathway involved in repairing ROS-induced DNA damage [32], as well as in preventing aging phenotypes [33]. SIRT6 is also a key regulator of glucose homeostasis [34]. Recently, it has been showed that mice deficient in SIRT6 develop abnormalities usually associated with premature aging phenotypes, including several metabolic defects, such as increase in fat accumulation, impaired glucose tolerance, and alteration in lipid homeostasis [35]. The main targets of SIRT6 are nuclear factor-kappa B (NF-κB), a transcription factor that plays pivotal roles in regulating aging, and inflammation as well as

| Characteristics                        | All (n = 1018) | Absence (n = 409) | Presence (n = 609) | p     |
|----------------------------------------|---------------|------------------|-------------------|-------|
| Age (yrs), Mean ± SD                   | 69.71 ± 8.84  | 66.34 ± 8.13     | 71.98 ± 8.58      | <0.0001 |
| Female, %                              | 60.71         | 64.79            | 57.96             | 0.03  |
| Race/ethnicity, %                      |               |                  |                   | 0.002 |
| White                                  | 14.83         | 10.76            | 17.57             |       |
| Black                                  | 16.6          | 14.67            | 17.9              |       |
| Hispanics                              | 66.8          | 72.62            | 62.89             |       |
| Other                                  | 1.77          | 1.96             | 1.64              |       |
| Education attainment (yrs), %          |               |                  |                   | 0.4   |
| ≤8                                     | 43.91         | 46.45            | 42.2              |       |
| 12-Sep                                 | 26.42         | 25.43            | 27.09             |       |
| >12                                    | 29.67         | 28.12            | 30.71             |       |
| Ever smoked, %                         | 52.16         | 43.28            | 58.13             | <0.0001 |
| Moderate alcohol drinking, %           | 41.36         | 41.32            | 41.38             | 0.98  |
| No leisure-time physical activity, %   | 43.71         | 42.54            | 44.5              | 0.88  |
| Hypertension (yes), %                  | 62.28         | 55.26            | 67                | 0.0002 |
| Diabetes (yes), %                      | 18.47         | 14.18            | 21.35             | 0.004 |
| Hypercholesterolemia (yes), %          | 27.11         | 24.21            | 29.06             | 0.09  |
| BMI (kg/m²), Mean ± SD                 | 28.56 ± 5.03  | 28.76 ± 5.02     | 28.43 ± 5.04      | 0.31  |
| WHR, Mean ± SD                         | 0.92 ± 0.08   | 0.91 ± 0.08      | 0.93 ± 0.08       | 0.0008|

Table 2. SNPs associated with presence or number of carotid plaque (Bonferroni-corrected p≤0.05).

| Carotid plaque | Chr | Gene | SNP   | Position (Mb) | Location | Minor allele (Freq.) | exp(beta) (95% CI)* | Nominal p | Adjusted p |
|----------------|-----|------|-------|---------------|----------|----------------------|---------------------|-----------|------------|
| Presence       | 19  | SIRT6| rs107251| 4127085       | Intron   | T (0.11)            | 1.71 (1.23–2.37)  | 0.001     | 0.03       |
| X              |     | UCP5 | rs5977238| 129308417    | Intron   | T (0.07)            | 0.49 (0.32–0.74)  | 0.0008    | 0.02       |
| Number         | 6   | SIRT5| rs4712032| 13662022     | Flanking | G (0.31)            | 1.14 (1.06–1.22)  | 0.0007    | 0.002      |
| X              |     | SIRT5| rs12216101| 13669021    | Flanking | G (0.21)            | 1.16 (1.07–1.26)  | 0.0004    | 0.01       |
| Presence       | 19  | SIRT6| rs107251| 4127085       | Intron   | T (0.11)            | 1.31 (1.18–1.45)  | 4.8×10⁻⁷   | 1.4×10⁻⁵   |
| X              |     | UCP5 | rs5977238| 129308417    | Intron   | T (0.07)            | 0.64 (0.52–0.78)  | 1.6×10⁻⁵   | 4.9×10⁻⁴   |

*Beta was estimated based on Logistic and Poisson regression, respectively, for presence and number of carotid plaque after adjusting for age, sex, smoking, hypertension, diabetes and waist-to-hip ratio as well as genomic control variables (PCAs).

Bonferroni-corrected p was based on the sum of singleton SNPs and LD blocks.

doi:10.1371/journal.pone.0027157.t001
doi:10.1371/journal.pone.0027157.t002
hypoxygen-inducible transcription factor HIF1α, an important regulator of glucose homeostasis that has been also linked to lifespan regulation [32]. The SIRT6 polymorphism identified in our study may well be interfering with NF-kB or HIF1α and contribute this way to an accelerated vascular aging.

Another main finding is the significant association between UCP5 variant rs5977238 and the risk of carotid plaque. Although the physiological function of UCP5 has not yet been fully established, it causes mild uncoupling by which it may diminish mitochondrial superoxide production, hence protecting against oxidative damage [37]. By attenuating superoxide generation and maintaining oxidative phosphorylation UCP5 may play a protective role against atherosclerosis and CVD. Interestingly, intergenic interaction analyses showed that among T-carriers of UCP5 rs5977238, individuals with the minor allele at the SNPs at the UCP1, SIRT3 and SIRT5 genes had an increased risk of having plaque. Sirtuins may control the genetic expression of UCPs by binding directly to their promoter [38,39]. Relationships between SIRTs and UCPs have been also

| Table 3. Haplotypes in the SIRT5, SIRT6 and UCP5 genes associated with carotid plaque (Bonferroni-corrected p ≤0.05). |
|-----------------------------------------------|
| **Gene** | **SNPs** | **Haplotype** | **Freq.** | **Carotid plaque exp(beta) (95% CI)** | **Nominal p** | **Adjusted p** |
| SIRT5 | rs4712032, rs1217526, rs10498683, rs12216101 (LD block 3) | GCGG | 0.21 | Number 1.16 (1.07–1.26) | 0.0004 | 0.009 |
| SIRT6 | rs107251, rs3760909 (LD block 13) | TT | 0.11 | Presence 1.67 (1.20–2.32) | 0.002 | 0.05 |
| UCP5 | rs6418932, rs12557276, rs2235800, rs16999665, rs5977248, rs4830187, rs4829716, rs4830188, rs5932754 (LD Block 16) | TTTACATT | 0.07 | Presence 0.45 (0.30–0.68) | 0.0002 | 0.005 |

*beta was estimated based on Logistic and Poisson regression, respectively, for presence and number of carotid plaque after adjusting for age, sex, smoking, hypertension, diabetes and waist-to-hip ratio as well as genomic control variables (PCAs).

Bonferroni corrected p based on 23 tested haplotypes with a frequency ≥5% in SIRT5, SIR6 and UCP5 genes.

| Table 4. SNPs showing interaction with sex and vascular risk factors for presence or number of carotid plaque with a nominal p ≤0.01. |
|-----------------------------------------------|
| **Carotid plaque** | **Vascular risk factor (VRF)** | **SNP (gene)** | **P_or** | **P_sn** | **P_interac** | **exp(beta) for interaction (95% CI)** | **Stratified analysis exp(beta) (95% CI) for 1 minor allele change** |
| Presence | Female | rs1685356 (UCP3) | 0.01 | 0.02 | 0.007 | 1.81 (1.17–2.79) | 1.42 (1.08–1.87) | 0.76 (0.54–1.08) |
| Number | Female | rs1726745 (UCP3) | 0.01 | 0.03 | 0.01 | 1.71 (1.13–2.59) | 1.38 (1.07–1.77) | 0.79 (0.56–1.10) |
| Smoking | Female | rs1430579 (UCP1) | 0.0004 | 0.0001 | 0.0003 | 1.30 (1.13–1.50) | 1.06 (0.97–1.16) | 0.80 (0.72–0.90) |
| Diabetes | Female | rs1472268 (UCP1) | 0.0006 | 0.0002 | 0.0005 | 1.29 (1.12–1.49) | 1.05 (0.96–1.15) | 0.80 (0.72–0.90) |
| Hypertension | Female | rs1472269 (UCP1) | 0.0005 | 0.0001 | 0.0005 | 1.30 (1.12–1.51) | 1.02 (0.93–1.13) | 0.78 (0.69–0.88) |
| Smoking | Female | rs6829571 (UCP1) | 0.0005 | 0.0003 | 0.0006 | 1.29 (1.12–1.49) | 1.07 (0.97–1.17) | 0.82 (0.73–0.91) |
| Diabetes | Female | rs2841503 (SIRT5) | <0.0001 | 0.0003 | 0.003 | 0.67 (0.52–0.87) | 0.96 (0.84–1.15) | 1.47 (1.20–1.82) |
| Hypertension | Female | rs6907892 (UCP4) | <0.0001 | 0.005 | 0.005 | 0.80 (0.69–0.93) | 0.91 (0.82–0.99) | 1.12 (1.00–1.26) |
| Diabetes | Female | rs10498683 (SIRT5) | <0.0001 | 0.09 | 0.03 | 0.67 (0.51–0.87) | 0.71 (0.55–0.90) | 1.00 (0.89–1.12) |
| Hypertension | Female | rs6418932 (UCP5) | <0.0001 | 0.28 | 0.06 | 0.77 (0.65–0.93) | 0.84 (0.71–1.00) | 1.04 (0.95–1.14) |
| Diabetes | Female | rs12557276 (UCP5) | <0.0001 | 0.02 | 0.008 | 0.76 (0.61–0.93) | 0.90 (0.74–1.10) | 1.14 (1.04–1.25) |
| Hypertension | Female | rs2235800 (UCP5) | <0.0001 | 0.25 | 0.004 | 0.76 (0.63–0.92) | 0.82 (0.69–0.98) | 1.05 (0.95–1.15) |
| Diabetes | Female | rs4830187 (UCP5) | <0.0001 | 0.02 | 0.004 | 0.74 (0.60–0.91) | 0.88 (0.72–0.70) | 1.14 (1.04–1.25) |
| Hypertension | Female | rs4830188 (UCP5) | <0.0001 | 0.34 | 0.006 | 0.76 (0.62–0.92) | 0.80 (0.66–0.97) | 1.04 (0.94–1.14) |
| Diabetes | Female | rs5932754 (UCP5) | <0.0001 | 0.37 | 0.009 | 0.77 (0.63–0.94) | 0.82 (0.68–0.99) | 1.03 (0.94–1.13) |
| Hypertension | Female | rs10498683 (SIRT5) | <0.0001 | 0.12 | 0.005 | 0.73 (0.58–0.91) | 0.84 (0.74–0.95) | 1.15 (0.96–1.38) |
| Diabetes | Female | rs9370232 (SIRT3) | <0.0001 | 0.21 | 0.0004 | 0.69 (0.56–0.85) | 0.77 (0.69–0.87) | 1.12 (0.94–1.33) |
| Hypertension | Female | rs536715 (SIRT3) | 0.003 | 0.0006 | 0.01 | 1.39 (1.08–1.78) | 0.95 (0.85–1.07) | 0.67 (0.54–0.84) |
| Diabetes | Female | rs5977238 (UCP5) | <0.0001 | 1 | 0.001 | 0.51 (0.34–0.77) | 0.51 (0.39–0.67) | 0.95 (0.69–1.30) |

*P_or, P_sn, P_interac, and beta were, respectively, p-value for risk factor main effect, p-value for SNP main effect, p-value and regression coefficient for their interactive effect, based on Logistic (plaque presence) and Poisson (plaque count) regression models after adjusting for age, sex, smoking, hypertension, diabetes and waist-to-hip ratio as well as genomic control variables (PCAs) if applicable.

doi:10.1371/journal.pone.0027157.t003

doi:10.1371/journal.pone.0027157.t004

*Nominal* and *Adjusted* p-values were obtained using Bonferroni correction.
stimuli, such as oxidative stress. The synergistic effect of SIRTs/UCPs might be necessary to inefficient blood vessel metabolism that can cause vascular aging availability of NO, evidence of oxidative stress, resulting in expression increases superoxide production and decreases the stress and protects against ROS-mediated damage [41]. UCP1 SIRT3 expression significantly increases in response to oxidative production and therefore the development of atherosclerosis. and SIRT5, which are mitochondrial SIRTs, in controlling ROS metabolism [40]. A recent study has indicated that UCP5 controls demonstrated in delay age-related disease by activating cellular metabolism [40]. A recent study has indicated that UCP5 controls the cellular mitochondrial membrane potential, ATP production and oxygen consumption [37]. This may interact with the SIRT3 and SIRT5, which are mitochondrial SIRTs, in controlling ROS production and therefore the development of atherosclerosis. SIRT3 expression significantly increases in response to oxidative stress and protects against ROS-mediated damage [41]. UCP1 expression increases superoxide production and decreases the availability of NO, evidence of oxidative stress, resulting in inefficient blood vessel metabolism that can cause vascular aging [9]. The synergistic effect of SIRTs/UCPs might be necessary to maintain oxidative balance and ATP production, and consequently cellular survival and modification in response to different stimuli, such as oxidative stress.

In the present study, we observed sex-specific effects of genetic variants in UCP1 and 3 genes on presence of carotid plaque in women. Difference in UCP3 exon 5 variants have been observed between African and white American women and suggested a role of UCP3 for the higher predisposition of obesity in African American women [42]. Interestingly, an experimental study has demonstrated an increase of UCP1 expression in female rats under stress [43]. Polymorphisms of UCP1 have been associated with fat metabolism, obesity, and diabetes [44,45], which are known to have different distributions in men and women. Sex hormones have been also shown to modulate UCP1 and UCP3 expression [46]. These findings may in part explain the sex-specific effect of UCP1 and 3 genetic variants on carotid plaque.

Smoking is one of the major lifestyle vascular factors. Life-long cigarette smokers have a higher prevalence of atherosclerosis and CVD through the increase of oxidative stress [47]. We found an interaction between smoking and SIRT5 and UCP4 variants for a decreased risk of plaque presence and plaque number. These interactions with smoking may be due to the control of ROS production. A direct association between smoking and UCPs has been found in mice where cigarette smoke exposure increased UCPs in the brown fat [48]. Further studies are needed to clarify the exact interaction between smoking and SIRTs and UCPs.

Some modifications by hypertension and diabetes were also observed in the association of SIRT3, SIRT5 and UCP5 genetic variants with carotid plaque. In experimental studies, SIRT3 expression has been regulated by Angiotensin II, which may play a pivotal role in the etiology of hypertension [49,50]. UCPs have shown to lower blood pressure in obese mice, suggesting a potential protective effect of UCP on atherosclerosis in type 2 diabetes [51]. Moreover, as well as SIRTs, UCPs genetic modulation in hypertensive rats have been demonstrated to have a cardioprotective effect by interacting with Angiotensin II in controlling ROS production [52]. The role of SIRTs and UCPs in diabetes has also been previously explored [53,54], and linked to atherosclerosis due to their direct effect on insulin release and regulation of the glucose substrate consumption in the endothelial cells by reducing ROS production [55].

Our results need to be taken with caution because of several limitations. First, our study included a relative small convenience sample with a few available SNPs in the sirtuin and UCP genes (7 sirtuin and 5 UCP genes for a total of 3055 SNPs, http://www.ncbi.nlm.nih.gov/snp). Second, the multiethnic nature and the heterogeneous origin of the study population may reduce the statistical power even thought using PCAs as genomic control in the analyses. Third, the interaction analyses were not adjusted for multiple testing and highly exploratory. Fourth, some traditional risk factors such as smoking, hypercholesterolemia and physical activity were dichotomized representing crude measures of these exposures. Despite these limitations, we observed novel associations of genetic variants in UCP1, 3, 4, and 5 and SIRT3, 5, and 6 with carotid plaque. Exploring the impact of these genes on vascular aging and premature atherosclerosis may be of particular importance for detecting asymptomatic individuals at increased risk for vascular disease. Moreover, it may aid to the development of a novel vascular preventive compounds such as resveratrol, a SIRT activator [56] in order to restore the impaired molecular
pathways, and thereby reduce atherosclerosis. Further research is imperative to confirm these findings.

Supporting Information

Figure S1 Linkage disequilibrium (LD) pattern in 10 sirtuin and mitochondrial uncoupling protein genes. Haploview program is used to calculate the D’ shown in each box are estimated statistics of the D’, which indicates the LD relationship between each pair of single nucleotide polymorphisms (SNPs) in each gene and are not labeled if D’ = 1.00.

Table S1 SIRT/UCP localization and biological effects on cardiovascular disease.

Reference:

1. Johnson SH, Mathiesen EB (2009) Carotid plaque compared with intra-media thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep 11: 21–27.

2. Dong C, Beecham A, Siffer S, Wang L, Blanton SH, et al. (2010) Genome-wide linkage and pool-wide association analyses of carotid plaque in Caribbean Hispanic. Stroke 41: 2750–2756.

3. Hunt KJ, Duggirala R, Goring HH, Williams JT, Almasy L, et al. (2002) Genetic basis of variation in carotid artery plaque in the San Antonio Family Heart Study. Stroke 33: 2773–2776.

4. Ramos K5, Pattridge CR, Tenen I (2007) Genetic and molecular mechanisms of chemical atherosclerosis. Mutat Res Rev 621: 18–30.

5. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Caiazzo A (2010) Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 65: 1028–1041.

6. Dalby-Nielsen N, Lagouge M, Froelich S, Kowal C, Schoonjans K, et al. (2007) Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med 39: 335–349.

7. Rousset S, Alves-Guerra MC, Mozo J, Miroux T, Casaroli MA, et al. (2004) The biology of mitochondrial uncoupling proteins. Diabetes 53 Suppl 1: S130–133.

8. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins—novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7: 841–853.

9. Bernal-Mizrachi C, Gates AC, Chinault SL, Feng C, Schneider JG, et al. (2007) Structure and biochemical functions of SIRT1. J Biol Chem 282: 14753–14757.

10. Peeters AV, Beckers S, Verrijken A, Mertens I, Roevens P, et al. (2008) Association of common variants of UCP2 gene with low-grade inflammation in Swedish children and adolescents; the European Youth Heart Study. Pediatr Res 63: 351–357.

11. Chen HY, Kim CH, Kim KS, Kang BK, Choi SM, et al. (2007) Association of UC2P and UC3P gene polymorphisms with serum high-density lipoprotein cholesterol among Korean women. Metabolism 56: 806–813.

12. Tabayen I, Ortega FB, Sjostrom M, Nilsson TK, Olsson LA, et al. (2009) Association of common variants of UCP2 gene with low-grade inflammation in Swedish children and adolescents; the European Youth Heart Study. Pediatr Res 66: 350–354.

13. Rundek T, Avril F, Boden-Alba B, Blennow MS, Paik MC, et al. (2008) Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. Neurology 70: 1200–1207.

14. Sacco RL, Marrie T, Joo SH, Huang JS, et al. (2007) Design of a family study among high-risk Caribbean Hispanics: the Northern Manhattan Study. Ethn Dis 17: 351–357.

15. Sacco RL, Khatri M, Rundek T, Xu Q, Gardener H, et al. (2009) Improving global vascular risk prediction with behavioral and anthropometric factors. The Multiethnic NOMAS (Northern Manhattan Observational) Study. Ethn Dis 19: 92–102.

16. Rundek T, Arif H, Boden-Alba B, Elkind MS, Paik MC, et al. (2008) Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. Neurology 70: 1200–1207.

17. Sacco RL, Marrie T, Joo SH, Huang JS, et al. (2007) Design of a family study among high-risk Caribbean Hispanics: the Northern Manhattan Study. Ethn Dis 17: 351–357.

18. Sacco RL, Khatri M, Rundek T, Xu Q, Gardener H, et al. (2009) Improving global vascular risk prediction with behavioral and anthropometric factors. The Multiethnic NOMAS (Northern Manhattan Observational) Study. Ethn Dis 19: 92–102.

19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.

20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) Reproductive uncoupling in skeletal muscle delays death and diminishes age-related disease. Cell Metab 9: 493–499.

21. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.

22. Nicolaides KK, Liu W, Chase GA, Tsai NY, Fallin MD (2005) Comparison of type I error for multiple test corrections in large single-nucleotide polymorphism studies using principal components versus haplotype blocking algorithms. BMC Genet 6 Suppl 1: S70.
47. Yanhaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. Chest 131: 1557–1566.
48. Chen H, Hansen MJ, Jones JE, Vlahos R, Anderson GP, et al. (2008) Long-term cigarette smoke exposure increases uncoupling protein expression but reduces energy intake. Brain Res 1220: 81–88.
49. Hao CM, Haase VH (2010) Sirtuins and their relevance to the kidney. J Am Soc Nephrol 21: 1620–1627.
50. Benigni A, Corra D, Zoja C, Sonnogna A, Latino R, et al. (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524–530.
51. Bernal-Mizrachi C, Weng S, Li B, Nolte LA, Feng C, et al. (2002) Respiratory uncoupling lowers blood pressure through a leptin-dependent mechanism in genetically obese mice. Arterioscler Thromb Vasc Biol 22: 961–968.
52. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, et al. (2006) Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 24: 1097–1104.
53. Dalgaard LT, Pedersen O (2001) Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes. Diabetologia 44: 946–965.
54. Elliott PJ, Jirousek M (2008) Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 9: 371–378.
55. Potente M (2010) An energy-sensor network takes center stage during endothelial aging. Circ Res 106: 1316–1318.
56. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, et al. (2010) Sirtuin activators: Designing molecules to extend life span. Biochim Biophys Acta 1799: 740–749.